|
1
|
Gu X, Wang C, Wang X, Ma G, Li Y, Cui L,
Chen Y, Zhao B and Li K: Efficient inhibition of human glioma
development by RNA interference-mediated silencing of PAK5. Int J
Biol Sci. 11:230–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meyer MA: Malignant gliomas in adults. N
Engl J Med. 359:1850author reply 1850. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ostrom QT, Gittleman H, Liao P, Rouse C,
Chen Y, Dowling J, Wolinsky Y, Kruchko C and Barnholtz-Sloan J:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the United States in 2007-2011. Neuro Oncol.
16(Suppl 4): iv1–iv63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang FY, Lee TW, Chang CH, Chen LC, Hsu
WH, Chang CW and Lo JM: Evaluation of (188) Re-labeled PEGylated
nanoliposome as a radionuclide therapeutic agent in an orthotopic
glioma-bearing rat model. Int J Nanomedicine. 10:463–473. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vredenburgh JJ, Desjardins A, Reardon DA,
Peters KB, Herndon JE II, Marcello J, Kirkpatrick JP, Sampson JH,
Bailey L, Threatt S, et al: The addition of bevacizumab to standard
radiation therapy and temozolomide followed by bevacizumab,
temozolomide and irinotecan for newly diagnosed glioblastoma. Clin
Cancer Res. 17:4119–4124. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Quick A, Patel D, Hadziahmetovic M,
Chakravarti A and Mehta M: Current therapeutic paradigms in
glioblastoma. Rev Recent Clin Trials. 5:14–27. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Karavitis J and Zhang M: COX2 regulation
of breast cancer bone metastasis. Oncoimmunology. 2:e231292013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsujii M and DuBois RN: Alterations in
cellular adhesion and apoptosis in epithelial cells overexpressing
prostaglandin endoperoxide synthase 2. Cell. 83:493–501. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Howe LR: Inflammation and breast cancer.
Cyclooxygenase/prostaglandin signaling and breast cancer. Breast
Cancer Res. 9:2102007. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tyagi A, Agarwal C, DwyerNield LD, Singh
RP, Malkinson AM and Agarwal R: Silibinin modulates TNF-α and IFN-γ
mediated signaling to regulate COX2 and iNOS expression in
tumorigenic mouse lung epithelial LM2 cells. Mol Carcinog.
51:832–842. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Martín Sanz P, Hortelano S, Bosca L and
Casado M: Cyclooxygenase 2: Understanding the pathophysiological
role through genetically altered mouse models. Front Biosci.
11:2876–2888. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Krzystyniak KL: Current strategies for
anticancer chemoprevention and chemoprotection. Acta Pol Pharm.
59:473–478. 2002.PubMed/NCBI
|
|
14
|
Farh KK, Grimson A, Jan C, Lewis BP,
Johnston WK, Lim LP, Burge CB and Bartel DP: The widespread impact
of mammalian MicroRNAs on mRNA repression and evolution. Science.
310:1817–1821. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamashita D, Kondo T, Ohue S, Takahashi H,
Ishikawa M, Matoba R, Suehiro S, Kohno S, Harada H, Tanaka J and
Ohnishi T: MiR-340 suppresses the stem-like cell function of
glioma-initiating cells by targeting tissue plasminogen activator.
Cancer Res. 75:1123–1133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu D, Zhou Y, Pan H, Zhou J, Fan Y and Qu
P: MicroRNA-99a inhibiting cell proliferation, migration and
invasion by targeting fibroblast growth factor receptor 3 in
bladder cancer. Oncol Lett. 7:1219–1224. 2014.PubMed/NCBI
|
|
17
|
Slaby O, Svoboda M, Fabian P, Smerdova T,
Knoflickova D, Bednarikova M, Nenutil R and Vyzula R: Altered
expression of miR-21, miR-31, miR-143 and miR-145 is related to
clinicopathologic features of colorectal cancer. Oncology.
72:397–402. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Silber J, Lim DA, Petritsch C, Persson AI,
Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello
JF, et al: MiR-124 and miR-137 inhibit proliferation of
glioblastoma multiforme cells and induce differentiation of brain
tumor stem cells. BMC Med. 6:142008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chan JA, Krichevsky AM and Kosik KS:
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells.
Cancer Res. 65:6029–6033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Chao T, Li R, Liu W, Chen Y, Yan
X, Gong Y, Yin B, Liu W, Qiang B, et al: MicroRNA-128 inhibits
glioma cells proliferation by targeting transcription factor E2F3a.
J Mol Med (Berl). 87:43–51. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lorimer IA: Regulation of p27Kip1 by miRNA
221/222 in glioblastoma. Cell Cycle. 8:26852009.PubMed/NCBI
|
|
23
|
Lou M and Zhao Y: Satisfactory therapy
results of combining nimustine with nicardipine against glioma at
advanced stage. J Cancer Res Ther. 11:10302015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dews M, Homayouni A, Yu D, Murphy D,
Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT and
Thomas-Tikhonenko A: Augmentation of tumor angiogenesis by a
Myc-activated microRNA cluster. Nat Genet. 38:1060–1065. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu C, Li H, Zhao H, Zhang W, Chen Y, Yue
Z, Lu Q, Wan Y, Tian X and Deng A: Potentiating antilymphoma
efficacy of chemotherapy using a liposome for integration of CD20
targeting, ultra-violet irradiation polymerizing and controlled
drug delivery. Nanoscale Res Lett. 9:4472014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bandrés E, Cubedo E, Agirre X, Malumbres
R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M and
García-Foncillas J: Identification by Real-time PCR of 13 mature
microRNAs differentially expressed in colorectal cancer and
non-tumoral tissues. Mol Cancer. 5:292006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li J, Yen C, Liaw D, Podsypanina K, Bose
S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al:
PTEN, a putative protein tyrosine phosphatase gene mutated in human
brain, breast and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hermanson M, Funa K, Hartman M,
ClaessonWelsh L, Heldin CH, Westermark B and Nistér M:
Platelet-derived growth factor and its receptors in human glioma
tissue: Expression of messenger RNA and protein suggests the
presence of autocrine and paracrine loops. Cancer Res.
52:3213–3219. 1992.PubMed/NCBI
|
|
29
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He L and Hannon GJ: MicroRNAs: Small RNAs
with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Gao J, Li L, Wu M, Liu M and Xie X, Guo J,
Tang H and Xie X: MiR-26a inhibits proliferation and migration of
breast cancer through repression of MCL-1. PLoS One. 8:e651382013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y,
Xu X, Wu J, Li S, Mao Q, et al: MiR-26a inhibits proliferation and
motility in bladder cancer by targeting HMGA1. FEBS Lett.
587:2467–2473. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Deng M, Tang HL, Lu XH, Liu MY, Lu XM, Gu
YX, Liu JF and He ZM: MiR-26a suppresses tumor growth and
metastasis by targeting FGF9 in gastric cancer. PLoS One.
8:e726622013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao S, Ye X, Xiao L, Lian X, Feng Y, Li F
and Li L: MiR-26a inhibits prostate cancer progression by
repression of Wnt5a. Tumour Biol. 35:9725–9733. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Verghese ET, Drury R, Green CA, Holliday
DL, Lu X, Nash C, Speirs V, Thorne JL, Thygesen HH, Zougman A, et
al: MiR-26b is down-regulated in carcinoma-associated fibroblasts
from ER-positive breast cancers leading to enhanced cell migration
and invasion. J Pathol. 231:388–399. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liang X, Liu Y, Zeng L, Yu C, Hu Z, Zhou Q
and Yang Z: MiR-101 inhibits the G1-to-S phase transition of
cervical cancer cells by targeting Fos. Int J Gynecol Cancer.
24:1165–1172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sheng Y, Li J, Zou C, Wang S, Cao Y, Zhang
J, Huang A and Tang H: Downregulation of miR-101-3p by hepatitis B
virus promotes proliferation and migration of hepatocellular
carcinoma cells by targeting Rab5a. Arch Virol. 159:2397–2410.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Edge SB, Sobin LH, Page DL, Gospodarowicz
MK, Greene FL and Winchester DP: Re: Colon cancer survival rates
with the new American Joint Committee on Cancer sixth edition
staging. J Natl Cancer Inst. 97:463–464. 2005. View Article : Google Scholar : PubMed/NCBI
|
